BioNTech SE
Change company Symbol lookup
Select an option...
BNTX BioNTech SE
ITRI Itron Inc
LTTTX MFS Lifetime 2025 Fund Class R3
HLI Houlihan Lokey Inc
KICK Master Glazier's Karate International Inc
VIRT Virtu Financial Inc
FB Facebook Inc
ED Consolidated Edison Inc
CLS Celestica Inc
HNHAF Hon Hai Precision Industry Co Ltd
Go

Health Care : Biotechnology |
Based in Germany
Company profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$101.59
Day's Change
-4.26 (-4.02%)
Bid
--
Ask
--
B/A Size
--
Day's High
104.99
Day's Low
97.25
Volume
(Average)
Volume:
3,151,568

10-day average volume:
2,992,308
3,151,568

Display:

Providers:

UpdateCancel
6 providers
January 08, 2021
Pfizer-BioNTech COVID-19-Impfstoff lost in vitro neutralisierende Antikorperantwort gegen SARS-CoV-2 mit einer Mutation aus, die mit einer schnellen Ubertragung assoziiert wird

New York und Mainz, Deutschland 08. Januar 2021 -- Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX) gaben heute Ergebnisse einer in vitro-Studie bekannt, die zeigen, dass Personen, die den Pfizer-BioNTech-COVID-19-Impfstoff erhalten haben...(Thomson Reuters ONE)

An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission

New York and Mainz, Germany, January 8, 2021 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies...(Thomson Reuters ONE)

January 07, 2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science

-- Collaborative study of BioNTech with TRON and the University Medical Center and Research Center for Immunotherapy at Johannes Gutenberg University of Mainz introduces novel non-inflammatory mRNA vaccine encoding disease-related autoantigens that...(Globe Newswire)

BioNTech veroffentlicht Daten zu neuartigem mRNA-Impfstoffansatz gegen Autoimmunkrankheiten in Science

- Gemeinsame Studie von BioNTech, TRON und der Universitatsmedizin sowie dem Forschungszentrum fur Immuntherapie der Johannes Gutenberg-Universitat Mainz untersucht neuartigen entzundungshemmenden mRNA-Impfstoff, der fur krankheitsassoziierte...(Thomson Reuters ONE)

BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science

- Collaborative study of BioNTech with TRON and the University Medical Center and Research Center for Immunotherapy at Johannes Gutenberg University of Mainz introduces novel non-inflammatory mRNA vaccine encoding disease-related autoantigens that...(Thomson Reuters ONE)

January 05, 2021
BioNTech prasentiert auf der 39. Annual J.P. Morgan Healthcare Conference

MAINZ, Deutschland, 5. Januar 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") gab heute bekannt, dass CEO und Mitgrunder Prof. Dr. Ugur Sahin das Unternehmen inklusive eines Unternehmensupdates auf der 39...(Thomson Reuters ONE)

BioNTech to Present at the 39th Annual J.P. Morgan Healthcare Conference

MAINZ, GERMANY, January 5, 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 39th Annual J.P. Morgan...(Thomson Reuters ONE)

BioNTech to Present at the 39th Annual J.P. Morgan Healthcare Conference

BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 39 Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021...(Globe Newswire)

January 04, 2021
ICON Supports Pfizer and BioNTech on the Investigational COVID-19 Vaccine Trial

ICON plc, (NASDAQ:ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public health organisations, today announced it...(BusinessWire)

December 29, 2020
Pfizer und BioNTech beliefern Europaische Union mit zusatzlichen 100 Millionen Dosen COMIRNATY(R)

- Europaische Union bestellt 100 Millionen zusatzliche Dosen COMIRNATY(R); damit erhalten die 27 EU-Mitgliedsstaaten insgesamt 300 Millionen Dosen - Alle 300 Millionen Dosen werden planmassig 2020 und 2021 ausgeliefert (Thomson Reuters ONE)

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY(R)

- European Union orders 100 million additional doses of COMIRNATY(R) bringing total doses to 300 million for 27 EU member states - All 300 million doses expected to be delivered in 2020 and 2021 NEW YORK and MAINZ, GERMANY, December 29, 2020 (GLOBE...(Thomson Reuters ONE)

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY(R)

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY(R), the companies' COVID-19 Vaccine, to the 27 European Union (EU) member states in 2021. This announcement is a...(BusinessWire)

December 23, 2020
Correction: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

-- U.S. government orders 100 million additional doses of the Pfizer-BioNTech COVID-19 vaccine bringing total doses for U.S. to 200 million -- All 200 million doses will be produced by U.S. manufacturing facilities and are expected to be delivered...(Globe Newswire)

Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

-- U.S. government orders 100 million additional doses of the Pfizer-BioNTech COVID-19 vaccine bringing total doses for U.S. to 200 million -- All 200 million doses will be produced by U.S. manufacturing facilities and are expected tobe delivered...(Globe Newswire)

Correction: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

- U.S. government orders 100 million additional doses of the Pfizer-BioNTech COVID-19 vaccine bringing total doses for U.S. to 200 million - All 200 million doses will be produced by U.S. manufacturing facilities and are expected to be delivered by...(Thomson Reuters ONE)

Correction: Pfizer und BioNTech beliefern USA mit zusatzlichen 100 Millionen COVID-19-Impfstoff-Dosen

- U.S.-Regierung bestellt 100 Millionen zusatzliche Dosen des Pfizer-BioNTech-COVID-19-Impftstoffes; dies erhoht die Gesamtzahl der Impfstoffdosen fur die USA auf 200 Millionen - Die 200 Millionen Impfstoffdosen werden in Produktionsstatten in den...(Thomson Reuters ONE)

Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

- U.S. government orders 100 million additional doses of the Pfizer-BioNTech COVID-19 vaccine bringing total doses for U.S. to 200 million - All 200 million doses will be produced by U.S. manufacturing facilities and are expected tobe delivered by...(Thomson Reuters ONE)

Pfizer und BioNTech beliefern USA mit zusatzlichen 100 Millionen COVID-19-Impfstoff-Dosen

- U.S.-Regierung bestellt 100 Millionen zusatzliche Dosen des Pfizer-BioNTech-COVID-19-Impftstoffes; dies erhoht die Gesamtzahl der Impfstoffdosen fur die USA auf 200 Millionen - Die 200 Millionen Impfstoffdosen werden in Produktionsstatten in den...(Thomson Reuters ONE)

Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies' COVID-19 Vaccine from production facilities in the U.S. This agreement...(BusinessWire)

December 21, 2020
BioNTech gibt Pressekonferenz zum Fortschritt im COVID-19-Impfstoffentwicklungsprogramm

MAINZ, Deutschland, 21. Dezember 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Dienstag, den 22. Dezember 2020, eine Pressekonferenz einschliesslich Videoubertragung abhalten, um ein Update zum Status...(Thomson Reuters ONE)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.